Scholar Rock Holding Corporatio (SRRK) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $47.56: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 16%; Below-average business quality.
Scholar Rock is a pre-commercial biopharma developing apitegromab, an anti-myostatin antibody, as potential first muscle-targeted therapy for SMA; Phase 3 SAPPHIRE was positive but BLA received a CRL in September 2025 due to third-party fill-finish facility GMP issues. Pipeline... Read more
Sell if holding. Engine safety override at $47.56: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 16%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 56, MACD bullish. Score 4.5/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Scholar Rock Holding Corporatio
Latest news
- Barclays Maintains Overweight on Scholar Rock Holding, Raises Price Target to $55 — benzinga May 8, 2026 positive
- HC Wainwright & Co. Maintains Buy on Scholar Rock Holding, Raises Price Target to $65 — benzinga May 8, 2026 positive
- Scholar Rock Holding Q1 EPS $(0.83), Inline — benzinga May 7, 2026 neutral
- Canaccord Genuity Initiates Coverage On Scholar Rock Holding with Buy Rating, Announces Price Target of $62 — benzinga Apr 21, 2026 positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineapitegromab (SMA)10-K Item 1: 'Commercialize apitegromab for children and adults living with SMA. We are developing our first product candidate, apitegromab, for the treatment of patients with SMA.'
- HIGHSupplierthird-party fill-finish facility10-K Item 1A: 'In September 2025, we received a CRL from the FDA citing observations identified during an FDA inspection of a third-party fill-finish facility.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $47.56: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 16%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 56, MACD bullish. Prior stop was $44.23. Score 4.5/10, moderate confidence.
Take-profit target: $53.10 (+11.6% upside). Prior stop was $44.23. Stop-loss: $44.23.
Concentration risk — Pipeline: apitegromab (SMA); Concentration risk — Supplier: third-party fill-finish facility; Quality below floor (1.5 < 4.0).
Scholar Rock Holding Corporatio trades at a P/E of N/A (forward -19.7). TrendMatrix value score: 6.0/10. Verdict: Sell.
23 analysts cover SRRK with a consensus score of 4.3/5. Average price target: $59.
What does Scholar Rock Holding Corporatio do?Scholar Rock is a pre-commercial biopharma developing apitegromab, an anti-myostatin antibody, as potential first...
Scholar Rock is a pre-commercial biopharma developing apitegromab, an anti-myostatin antibody, as potential first muscle-targeted therapy for SMA; Phase 3 SAPPHIRE was positive but BLA received a CRL in September 2025 due to third-party fill-finish facility GMP issues. Pipeline also includes SRK-439 (Phase 1) and STK-002-class programs.